Halozyme Therapeutics, Inc.
HALO
$64.32
$0.020.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 60.46% | 67.42% | 24.74% | 93.92% | 47.98% |
| Total Depreciation and Amortization | -1.34% | -1.06% | -1.44% | -1.23% | 190.88% |
| Total Amortization of Deferred Charges | 0.88% | 0.93% | 0.99% | -0.27% | -0.22% |
| Total Other Non-Cash Items | -130.05% | 66.00% | 24.99% | -19.83% | -1.64% |
| Change in Net Operating Assets | 197.21% | -344.22% | -69.70% | 56.04% | -413.80% |
| Cash from Operations | 74.36% | -12.87% | -16.53% | 48.83% | 24.14% |
| Capital Expenditure | -17.57% | 48.47% | -259.09% | 68.84% | -10.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 671.24% | -106.15% | -173.93% | -62.21% | 39.33% |
| Cash from Investing | 455.57% | -100.70% | -176.44% | -37.43% | -374.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 50.63% | 352.60% | 287.65% | -- | -65.85% |
| Repurchase of Common Stock | 0.91% | -- | -- | 99.68% | -25,229,900.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.40% | 352.60% | 287.65% | 99.70% | -4,048.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 75.32% | -163.22% | -81.30% | 133.57% | -279.07% |
